99 related articles for article (PubMed ID: 9071742)
1. Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol.
Maybruck WM; Markaverich BM
Steroids; 1997 Mar; 62(3):321-30. PubMed ID: 9071742
[TBL] [Abstract][Full Text] [Related]
2. Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth.
Markaverich BM; Gregory RR; Alejandro MA; Varma RS; Johnson GA; Middleditch BS
J Steroid Biochem; 1989 Nov; 33(5):867-76. PubMed ID: 2601331
[TBL] [Abstract][Full Text] [Related]
3. Preliminary assessment of luteolin as an affinity ligand for type II estrogen--binding sites in rat uterine nuclear extracts.
Markaverich BM; Gregory RR
Steroids; 1993 Jun; 58(6):268-74. PubMed ID: 8212072
[TBL] [Abstract][Full Text] [Related]
4. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth.
Markaverich BM; Gregory RR; Alejandro M; Kittrell FS; Medina D; Clark JH; Varma M; Varma RS
Cancer Res; 1990 Mar; 50(5):1470-8. PubMed ID: 2302712
[TBL] [Abstract][Full Text] [Related]
5. Purification and characterization of nuclear type II [(3)H]estradiol binding sites from the rat uterus: covalent labeling with [(3)H]luteolin.
Markaverich BM; Shoulars K; Brown MA
Steroids; 2001 Sep; 66(9):707-19. PubMed ID: 11546559
[TBL] [Abstract][Full Text] [Related]
6. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones.
Markaverich BM; Schauweker TH; Gregory RR; Varma M; Kittrell FS; Medina D; Varma RS
Cancer Res; 1992 May; 52(9):2482-8. PubMed ID: 1568218
[TBL] [Abstract][Full Text] [Related]
7. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites.
Markaverich BM; Gregory RR; Alejandro MA; Clark JH; Johnson GA; Middleditch BS
J Biol Chem; 1988 May; 263(15):7203-10. PubMed ID: 3366774
[TBL] [Abstract][Full Text] [Related]
8. Methyl-p-hydroxyphenyllactate-esterase activity and type-II estrogen-binding sites in ovarian cancer: correlation with biological and clinico-pathological parameters.
Ranelletti FO; Scambia G; Benedetti Panici P; Piantelli M; Ferrandina G; D'Agostino G; De Vincenzo R; Rinelli A; Isola G; Mancuso S
Int J Cancer; 1995 Sep; 62(5):536-41. PubMed ID: 7665223
[TBL] [Abstract][Full Text] [Related]
9. Nuclear type-ii [h-3] estradiol binding-sites in mcf-7 human breast-cancer cells - binding interactions with 2,6-bis-([3,4-dihydroxyphenyl]-methylene)cyclohexanone esters and inhibition of cell-proliferation.
Markaverich B; Varma M; Densmore C; Tiller A; Schauweker T; Gregory R
Int J Oncol; 1994 Jun; 4(6):1291-300. PubMed ID: 21567051
[TBL] [Abstract][Full Text] [Related]
10. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Markaverich BM; Alejandro MA
Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
[TBL] [Abstract][Full Text] [Related]
11. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition.
Markaverich BM; Roberts RR; Alejandro MA; Johnson GA; Middleditch BS; Clark JH
J Steroid Biochem; 1988; 30(1-6):71-8. PubMed ID: 3386279
[TBL] [Abstract][Full Text] [Related]
12. Naringenin: a weakly estrogenic bioflavonoid that exhibits antiestrogenic activity.
Ruh MF; Zacharewski T; Connor K; Howell J; Chen I; Safe S
Biochem Pharmacol; 1995 Oct; 50(9):1485-93. PubMed ID: 7503800
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo inhibition of nuclear type II estrogen binding sites in the dorsolateral prostate of noble rats.
Ho SM; Viccione T; Yu M
J Steroid Biochem Mol Biol; 1993 Oct; 46(4):489-95. PubMed ID: 8217879
[TBL] [Abstract][Full Text] [Related]
14. An improved method for the quantification and recovery of rat uterine nuclear type II [3H]estradiol binding sites immobilized on a glass fiber matrix.
Densmore CL; Tiller AA; Gregory RR; Schauweker TH; Webb B; Markaverich BM
Steroids; 1995 Feb; 60(2):214-9. PubMed ID: 7618188
[TBL] [Abstract][Full Text] [Related]
15. Nuclear type II [3H]estradiol binding sites: a histone H3-H4 complex.
Shoulars K; Rodrigues MA; Crowley JR; Turk J; Thompson T; Markaverich BM
J Steroid Biochem Mol Biol; 2005 Jun; 96(1):19-30. PubMed ID: 15878266
[TBL] [Abstract][Full Text] [Related]
16. Type II estrogen binding site agonist: synthesis and biological evaluation of the enantiomers of methyl-para-hydroxyphenyllactate (MeHPLA).
Pretlow L; Williams R; Elliott M
Chirality; 2003 Oct; 15(8):674-9. PubMed ID: 12923805
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of rat urinary esterase A1.
Nakamura M; Takaoka M; Nishii M; Morimoto S
Biochim Biophys Acta; 1986 Nov; 884(2):311-8. PubMed ID: 3094589
[TBL] [Abstract][Full Text] [Related]
18. Characterization and partial purification of an estrogen type II binding site in chick oviduct cytosol.
Densmore CL; Markaverich BM; O'Malley BW; Clark JH
Biochemistry; 1989 Sep; 28(19):7788-96. PubMed ID: 2611214
[TBL] [Abstract][Full Text] [Related]
19. An endogenous ligand for type II binding sites in normal and neoplastic tissues.
Clark JH; Markaverich BM
Adv Exp Med Biol; 1986; 196():305-15. PubMed ID: 3716924
[TBL] [Abstract][Full Text] [Related]
20. Hormonally sensitive esterase activity in the mouse uterus results from uptake of plasma esterase.
Kadner SS; Katz J; Berliner BA; Levitz M; Finlay TH
Endocrinology; 1984 Dec; 115(6):2406-17. PubMed ID: 6499775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
